To evaluate the magnitude and duration of the antihypertensive effect of sustained release
(SRO) isradipine, 37 uncomplicated essential hypertensive patients (diastolic blood …

A randomized, double‐blind, placebo controlled study evaluated the effects on 24 h
ambulatory blood pressure (ABP) of isradipine sustained release (I‐SRO) administered …

In this study we used casual and 24-h blood pressure (BP) monitoring and Doppler
echocardiographic data to investigate the antihypertensive and hemodynamic effects of …

The antihypertensive efficacy of sustained-release isradipine administered once daily
compared to the immediate-release formulation administered twice daily was assessed by …

Twelve patients with essential hypertension were randomized in a double-blind cross-over
study to investigate the blood pressure BP-lowering activity of isradipine regular formulation …

A total of 190 patients (mean age 57 years; range 21 to 89 years), with a supine diastolic
blood pressure (sDBP) of 100 to 120 mm Hg after a 3-week placebo phase, entered a …

Isradipine controlled release (ISR-CR) is a reformulated long-acting dihydropyridine calcium
channel blocker. Its long-term antihypertensive effects and safety were tested in a 52-week …

Isradipine, a new calcium channel blocker, was given to 32 patients with mild to moderate
essential hypertension. After a run-in period of three weeks, 32 patients were randomized …

In a double-blind, parallel-group comparative study, once-daily administration of a modified-
release formulation of isradipine (Im, n= 189) was compared with twice-daily administration …

Synopsis Since the earlier review in Drugs substantial additional data have accumulated
regarding the antihypertensive efficacy of isradipine in various clinical situations, as well as …